Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system

Hani M. Babiker, Ali McBride, Michael Newton, Leigh M. Boehmer, Adrienne Goeller Drucker, Mollie Gowan, Manouchkathe Cassagnol, Todd D Camenisch, Faiz - Anwer, James M. Hollands

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. Hence, full knowledge of cardiovascular complications of chemotherapeutic agents, essential diagnostics tests to order, and appropriate management is paramount to oncologist, oncology pharmacists, and scientific clinical investigators. The aforementioned is particularly true in the current oncology era of plenteous early clinical trials studying several pathway/molecular-targeting agents with an increased cardiotoxic potential and the rapid expedited approval of those drugs by the FDA. Herein, we present a review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer.

Original languageEnglish (US)
Pages (from-to)186-200
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Volume126
DOIs
StatePublished - Jun 1 2018

Fingerprint

Molecular Targeted Therapy
Cardiovascular System
Drug Therapy
Drug Approval
Neoplasms
Pharmacists
Routine Diagnostic Tests
Pharmaceutical Preparations
Early Diagnosis
Research Personnel
Clinical Trials
Guidelines
Morbidity
Therapeutics

Keywords

  • Adverse effects
  • Anthracyclines
  • Antineoplastics
  • Cardio-oncology
  • Chemotherapy
  • Heart failure
  • Molecular targeted therapies
  • Monoclonal antibodies
  • Patient safety
  • QTc prolongation
  • Taxanes
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Cardiotoxic effects of chemotherapy : A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. / Babiker, Hani M.; McBride, Ali; Newton, Michael; Boehmer, Leigh M.; Drucker, Adrienne Goeller; Gowan, Mollie; Cassagnol, Manouchkathe; Camenisch, Todd D; Anwer, Faiz -; Hollands, James M.

In: Critical Reviews in Oncology/Hematology, Vol. 126, 01.06.2018, p. 186-200.

Research output: Contribution to journalReview article

Babiker, Hani M. ; McBride, Ali ; Newton, Michael ; Boehmer, Leigh M. ; Drucker, Adrienne Goeller ; Gowan, Mollie ; Cassagnol, Manouchkathe ; Camenisch, Todd D ; Anwer, Faiz - ; Hollands, James M. / Cardiotoxic effects of chemotherapy : A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. In: Critical Reviews in Oncology/Hematology. 2018 ; Vol. 126. pp. 186-200.
@article{50a066baddb64cd7bbbcc70570c01b03,
title = "Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system",
abstract = "Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. Hence, full knowledge of cardiovascular complications of chemotherapeutic agents, essential diagnostics tests to order, and appropriate management is paramount to oncologist, oncology pharmacists, and scientific clinical investigators. The aforementioned is particularly true in the current oncology era of plenteous early clinical trials studying several pathway/molecular-targeting agents with an increased cardiotoxic potential and the rapid expedited approval of those drugs by the FDA. Herein, we present a review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer.",
keywords = "Adverse effects, Anthracyclines, Antineoplastics, Cardio-oncology, Chemotherapy, Heart failure, Molecular targeted therapies, Monoclonal antibodies, Patient safety, QTc prolongation, Taxanes, Tyrosine kinase inhibitors",
author = "Babiker, {Hani M.} and Ali McBride and Michael Newton and Boehmer, {Leigh M.} and Drucker, {Adrienne Goeller} and Mollie Gowan and Manouchkathe Cassagnol and Camenisch, {Todd D} and Anwer, {Faiz -} and Hollands, {James M.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.critrevonc.2018.03.014",
language = "English (US)",
volume = "126",
pages = "186--200",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Cardiotoxic effects of chemotherapy

T2 - A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system

AU - Babiker, Hani M.

AU - McBride, Ali

AU - Newton, Michael

AU - Boehmer, Leigh M.

AU - Drucker, Adrienne Goeller

AU - Gowan, Mollie

AU - Cassagnol, Manouchkathe

AU - Camenisch, Todd D

AU - Anwer, Faiz -

AU - Hollands, James M.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. Hence, full knowledge of cardiovascular complications of chemotherapeutic agents, essential diagnostics tests to order, and appropriate management is paramount to oncologist, oncology pharmacists, and scientific clinical investigators. The aforementioned is particularly true in the current oncology era of plenteous early clinical trials studying several pathway/molecular-targeting agents with an increased cardiotoxic potential and the rapid expedited approval of those drugs by the FDA. Herein, we present a review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer.

AB - Cardiotoxic effects of chemotherapy and targeted drugs are ubiquitous and challenging in the field of oncology therapeutics. The broad spectrum of toxicities ranging from ischemic, hypertensive, cardiomyopathic, and arrhythmic complications can present as a significant challenge for clinicians treating cancer patients. If early diagnosis and intervention of cardiotoxic complications is missed, this can lead to delay or abrogation of planned treatment, which can potentially culminate to significant morbidity due to not only the cardiotoxic complications but also the progression of cancer. Hence, full knowledge of cardiovascular complications of chemotherapeutic agents, essential diagnostics tests to order, and appropriate management is paramount to oncologist, oncology pharmacists, and scientific clinical investigators. The aforementioned is particularly true in the current oncology era of plenteous early clinical trials studying several pathway/molecular-targeting agents with an increased cardiotoxic potential and the rapid expedited approval of those drugs by the FDA. Herein, we present a review discussing cardiotoxic effects of drugs and guidelines for management of the toxicities to assist the medical field in general managing patients with cancer.

KW - Adverse effects

KW - Anthracyclines

KW - Antineoplastics

KW - Cardio-oncology

KW - Chemotherapy

KW - Heart failure

KW - Molecular targeted therapies

KW - Monoclonal antibodies

KW - Patient safety

KW - QTc prolongation

KW - Taxanes

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85045672835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045672835&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2018.03.014

DO - 10.1016/j.critrevonc.2018.03.014

M3 - Review article

C2 - 29759560

AN - SCOPUS:85045672835

VL - 126

SP - 186

EP - 200

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -